



A Discussion of Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial

Hosted by William H. Sauer, MD, FHRS, CCDS

Article Information:

Article for Discussion: Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial

Authors: Linda P.T. Joosten, MD, Sander van Doorn MD, PhD, Peter M. van de Ven, PhD, Bart T.G. Köhlen, Melchior C. Nierman, MD, PhD, Huiberdina L. Koek, MD, PhD, Martin E.W. Hemels, MD, PhD, Menno V. Huisman, MD, PhD, Marieke Kruip, MD, PhD, Laura M. Faber, MD, PhD, Nynke M. Wiersma, MD, Wim F., Rob Fijnheer, MD, PhD, Henk J. Adriaansen, MD, PhD, Kit C. Roes, PhD, Arno W. Hoes, MD, PhD, Frans H. Rutten MD, PhD, Geert-Jan Geersing MD, PhD

Publication: [Circulation: AHA Journals](#)



Today's Host




William H. Sauer, MD, FHRF, CCDS
Brigham and Women's Hospital



Today's Contributors:



Erik Andrews, MD, MPH
Brigham and Women's Hospital



Christian Thomas Ruff, MD, MPH
Brigham and Women's Hospital



Disclosures:

William H. Sauer, MD, FHRS, CCDS

- **Honoraria/Speaking/Consulting:** Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific
- **Research:** Medtronic

Erik Andrews, MD, MPH

- **Nothing to disclose.**

Christian Thomas Ruff, MD, MPH

- **Honoraria/Speaking/Consulting:** Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals
- **Research:** Daiichi, MedImmune





Thank you!